Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 0.82 |
| ▸ | MEN1 | O00255 | 5/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.82 |
| ▸ | LMNA | P02545 | 3/20 | 0.82 |
| ▸ | STAT3 | P40763 | 2/20 | 0.82 |
| ▸ | GAA | P10253 | 3/20 | 0.80 |
| ▸ | GALR3 | O60755 | 1/20 | 0.80 |
| ▸ | NPY1R | P25929 | 1/20 | 0.80 |
| ▸ | NPY2R | P49146 | 1/20 | 0.80 |
| ▸ | HTT | P42858 | 1/20 | 0.76 |
| ▸ | POLB | P06746 | 4/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1143516 | 0.91 | MEN1 (0.89) | SMN1; SMN2MAPTMEN1KMT2ALMNA | |
| SCHEMBL14132905 | 0.91 | SMN1; SMN2 (1.00) | SMN1; SMN2MAPTMEN1KMT2ALMNA | |
| SCHEMBL19924937 | 0.85 | SMN1; SMN2 (0.74) | SMN1; SMN2MAPTMEN1KMT2ALMNA | |
| SCHEMBL4146159 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2MAPTMEN1KMT2ALMNA | |
| SCHEMBL15048510 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2MAPTMEN1KMT2ALMNA | |
| SCHEMBL13974492 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2MAPTMEN1KMT2ALMNA | |
| SCHEMBL7041013 | 0.79 | SMN1; SMN2 (0.66) | SMN1; SMN2MAPTMEN1KMT2ALMNA | |
| SCHEMBL28109720 | 0.79 | SMN1; SMN2 (0.66) | SMN1; SMN2MAPTMEN1KMT2ALMNA | |
| SCHEMBL7041015 | 0.79 | SMN1; SMN2 (0.66) | SMN1; SMN2MAPTMEN1KMT2ALMNA | |
| SCHEMBL891383 | 0.78 | SMN1; SMN2 (0.64) | SMN1; SMN2MAPTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070130702-A1 | Dyeing process using a specific compound containing active methylene and a compound chosen from a specific aldehyde, a specific ketone, a quinone and a diiminoisoindoline or 3-aminoisoindolone derivative | L'OREAL S.A. | 2007-06-14 | — | — | US | claimed |
| EP-1434552-A1 | METHOD FOR DYEING KERATINOUS FIBRES | Henkel Kommanditgesellschaft auf Aktien (DE) | 2004-07-07 | — | — | EP | claimed |
| WO-2003030841-A1 | METHOD FOR DYEING KERATINOUS FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2003-04-17 | — | — | WO | claimed |
| CN-102119047-B | Heteroaryl derivatives as DGAT1 inhibitors | NOVARTIS AG | 2014-09-24 | — | — | CN | disclosed |
| US-8703761-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-04-22 | — | — | US | disclosed |
| EP-2559455-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| EP-2548618-A2 | Organic compounds | Novartis AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | THE TRUSTEES OF DARTMOUTH COLLEGE | 2012-11-29 | — | — | US | disclosed |
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | THE TRUSTEES OF DARTMOUTH COLLEGE | 2012-11-29 | — | — | US | disclosed |
| EP-2380631-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| EP-2349484-A2 | HETEROARYL DERIVATIVES AS DGAT1 INHIBITORS | Novartis AG (CH) | 2011-08-03 | — | — | EP | disclosed |
| EP-1056433-B1 | DYEING METHOD USING A SPECIFIC ACTIVE METHYLENE COMPOUND AND A COMPOUND SELECTED AMONG A SPECIFIC ALDEHYDE, A SPECIFIC KETONE, A QUINONE AND A DI-IMINO-ISOINDOLINE OR 3-AMINO-ISOINDOLONE DERIVATIVE | OREAL (FR) | 2005-05-11 | — | — | EP | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
| WO-2004058203-A2 | AGENT FOR DYEING FIBRES CONTAINING KERATIN | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058202-A1 | DYE TABLETS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2004-07-15 | — | — | WO | disclosed |
| EP-1434552-A1 | METHOD FOR DYEING KERATINOUS FIBRES | Henkel Kommanditgesellschaft auf Aktien (DE) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003030841-A1 | METHOD FOR DYEING KERATINOUS FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2003-04-17 | — | — | WO | disclosed |
| EP-1056433-A1 | DYEING METHOD USING A SPECIFIC ACTIVE METHYLENE COMPOUND AND A COMPOUND SELECTED AMONG A SPECIFIC ALDEHYDE, A SPECIFIC KETONE, A QUINONE AND A DI-IMINO-ISOINDOLINE OR 3-AMINO-ISOINDOLONE DERIVATIVE | L'OREAL (FR) | 2000-12-06 | — | — | EP | disclosed |
| WO-2000038638-A1 | DYEING METHOD USING A SPECIFIC ACTIVE METHYLENE COMPOUND AND A COMPOUND SELECTED AMONG A SPECIFIC ALDEHYDE, A SPECIFIC KETONE, A QUINONE AND A DI-IMINO-ISOINDOLINE OR 3-AMINO-ISOINDOLONE DERIVATIVE | L'OREAL (FR) | 2000-07-06 | — | — | WO | disclosed |
| US-4246410-A | BENZINDOLE DYES OF YELLOW AND RED | CIBA -GEIGY AKTIENGESELLSCHAFT (CH) | 1981-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070130702-A1 | Dyeing process using a specific compound containing active methylene and a compound chosen from a specific aldehyde, a specific ketone, a quinone and a diiminoisoindoline or 3-aminoisoindolone derivative | KRT18, NDUFB5, NDUFB7 | SMN1; SMN2 3654/4885MAPT 685/4885MEN1 2976/4885 |
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | NRAS, HRAS, KRAS | SMN1; SMN2 1031/4885MAPT 2885/4885MEN1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.